Valuation: VolitionRx Limited

Market Cap 9.83M 8.59M 7.95M 7.29M 13.8M 947M 14.04M 94.76M 37.23M 463M 36.91M 36.1M 1.6B P/E 2026 *
-0.53x
P/E 2027 * -0.85x
Enterprise Value 9.83M 8.59M 7.95M 7.29M 13.8M 947M 14.04M 94.76M 37.23M 463M 36.91M 36.1M 1.6B EV / Sales 2026 *
3.97x
EV / Sales 2027 * 1.71x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day+0.42%
1 week-11.19%
Current month-11.85%
1 month-15.00%
3 months-66.23%
6 months-79.71%
Current year-76.72%
1 week 1.16
Extreme 1.155
1.53
1 month 1.16
Extreme 1.155
1.53
Current year 1.16
Extreme 1.155
7.73
1 year 1.16
Extreme 1.155
16
3 years 1.16
Extreme 1.155
31
5 years 1.16
Extreme 1.155
82.8
10 years 1.16
Extreme 1.155
136.8
Manager TitleAgeSince
Chief Executive Officer 55 05/10/2011
Director of Finance/CFO 56 31/01/2021
Chief Tech/Sci/R&D Officer 49 31/03/2024
Director TitleAgeSince
Director/Board Member 55 05/10/2011
Director/Board Member 77 05/10/2011
Director/Board Member 64 08/10/2019
Date Insider Type Main position Quantity % Market Cap.
17/03/26 Tax

Chief Technology Officer

5,310 0.0039%
17/03/26
Concord International, Inc.
OtherCompany 0 0%
17/03/26 Tax

Company Secretary

3,948 0.0029%
Change 5-day change 1-year change 3-year change Capi.($)
+0.85%-11.19%-91.50%-95.92% 9.83M
-0.37%+0.25%+136.19%+98.70% 4.75B
-4.00%+1.06%+103.42%+198.91% 3.67B
+1.77%+10.87%-25.08%-35.72% 2.12B
+1.16%+10.41%+116.37%-39.84% 2.12B
+30.03%+30.85%+98.39%+276.38% 1.54B
-0.36%+17.00%+177.18%-44.21% 1.04B
-2.39%+1.06%-11.61%+37.26% 894M
+5.64%+11.23%-30.48%-8.55% 507M
-3.06%+4.84%+5.11% - 490M
Average +2.85%+5.94%+47.80%+43.00% 1.71B
Weighted average by Cap. +1.98%+8.74%+89.33%+86.84%

Financials

2026 *2027 *
Net sales 2.48M 2.17M 2M 1.84M 3.48M 239M 3.54M 23.89M 9.38M 117M 9.3M 9.1M 403M 5.73M 5.01M 4.63M 4.25M 8.05M 552M 8.19M 55.27M 21.71M 270M 21.53M 21.06M 931M
Net income -22.2M -19.41M -17.95M -16.47M -31.17M -2.14B -31.71M -214M -84.08M -1.04B -83.38M -81.55M -3.61B -19.62M -17.15M -15.86M -14.55M -27.54M -1.89B -28.02M -189M -74.3M -923M -73.68M -72.06M -3.19B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
16/07/26 US$1.160 -1.69% 88,529
15/07/26 US$1.180 -7.09% 167,899
14/07/26 US$1.270 -2.31% 161,696
13/07/26 US$1.300 -3.70% 130,769
10/07/26 US$1.350 +0.75% 395,279
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.180USD
Average target price
16.97USD
Spread / Average Target
+1,337.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock